Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T16:41:43.124Z.
Calculation as of: 2026-10-06T16:41:43.124Z.
Quote observation: 2026-10-06T16:24:38.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5275dea95979b783385bf47589e59696b88cb0a7810ad834bc8fbd7b091458bc
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$7.31M
Price/FCF Ratio
N/A
TTM Avg
41006.18
3Y Avg
41006.18
5Y Avg
41006.18
Market Cap
$6.98M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.94M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CNS Pharmaceuticals, Inc. (CNSP) | $7.34M | N/A | N/A | N/A | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | N/A | 41006.18 | 41006.18 | 41006.18 |
| Longeveron Inc. (LGVN)vs › | $7.27M | N/A | N/A | N/A | N/A |
| Skye Bioscience, Inc. (SKYE)vs › | $7.25M | N/A | N/A | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.16M | N/A | N/A | N/A | N/A |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.59M | N/A | N/A | N/A | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.00M | N/A | N/A | N/A | N/A |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $6.98M | N/A | N/A | N/A | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $6.94M | N/A | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $6.78M | N/A | 6.05 | 13.36 | 13.36 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
